LALPATHLAB2021-01-012021-03-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2021-01-012021-03-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2021-01-012021-03-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2021-01-012021-03-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2020-04-01 2021-03-31 2021-05-13 INR Millions Yearly true Cash Flow Indirect Single segment There is no reportable segment for the company in accordance with the requirement of INDAS 108-Opearting Segments 2021-01-01 2021-03-31 Unaudited Standalone 4041000000.00 131000000.00 4172000000.00 965000000.00 0.00 0.00 712000000.00 39000000.00 179000000.00 1230000000.00 3125000000.00 1047000000.00 0.00 1047000000.00 244000000.00 16000000.00 260000000.00 0.00 787000000.00 0.00 0.00 0.00 0.00 787000000.00 -8000000.00 779000000.00 0.00 0.00 833000000.00 10 9.52 9.50 0.00 0.00 9.52 9.50 1. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 21 May, 2021. The financial results for the year ended 31 March, 2021 have been audited and for the quarter ended 31 March, 2021 have been reviewed by the statutory auditors of the Company and they have expressed an unmodified opinion thereon. 2. These financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India. 3. Figures for the quarter ended 31 March, 2021 and 31 March, 2020 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2020 and 31 December, 2019 respectively, which was subjected to limited review. 4. During the year ended 31 March, 2021 the Company has made a further investment of INR 225.00 million in its wholly owned subsidiary, PathLabs Unifiers Private Limited, through subscription of additional equity shares. Subsquent to the year ended 31 March, 2021 the Company has made a further investment of INR 45.00 million in its wholly owned subsidiary, PathLabs Unifiers Private Limited, through subscription of additional equity shares. 5. During the year ended 31 March, 2021 the Company has made a further investment of INR 40 million (KES 59 million) in its wholly owned subsidiary, Dr. Lal PathLabs Kenya Private Limited, through subscription of additional equity shares. 6. The Board of Directors of the Company had approved first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 6 November, 2020 which has been paid during the quarter ended on 31 December, 2020.The Board of Directors of the Company had approved second interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 29 January, 2021 which has been paid during the quarter ended on 31 March, 2021.The Board of Directors of the Company has proposed a final dividend of INR 8 per equity share (face value of Rs. 10 each) for the financial year ended 2020-2021. The total dividend for the year including the final dividend (Subject to approval of shareholders at the ensuing Annual General meeting) is Rs. 20 per equity share having face value of Rs. 10 each. 7. The Board of Directors in their meeting held on 3 February, 2020 had approved the “Scheme of Amalgamation” of APL Institute of Clinical Laboratory & Research Private Limited with the Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals. Due to size contraint, please refer notes mentioned in filed pdf file. Single segment 2020-04-01 2021-03-31 Audited Standalone 14905000000.00 513000000.00 15418000000.00 3739000000.00 0.00 0.00 2574000000.00 148000000.00 698000000.00 4518000000.00 11677000000.00 3741000000.00 0.00 3741000000.00 985000000.00 -45000000.00 940000000.00 0.00 2801000000.00 0.00 0.00 0.00 0.00 2801000000.00 -7000000.00 2794000000.00 0.00 0.00 833000000.00 10 11338000000.00 33.93 33.85 0.00 0.00 33.93 33.85 Fees to collection centers/channel partners 572000000.00 Other expenses 658000000.00 Fees to collection centers/channel partners 2007000000.00 Other expenses 2511000000.00 148000000.00 161000000.00 -172000000.00 0.00 48000000.00 0.00 -23000000.00 0.00 0.00 234000000.00 0.00 79000000.00 0.00 698000000.00 39000000.00 15000000.00 0.00 32000000.00 0.00 0.00 16000000.00 427000000.00 204000000.00 0.00 0.00 0.00 -6000000.00 -50000000.00 0.00 964000000.00 4705000000.00 0.00 0.00 0.00 971000000.00 0.00 3734000000.00 0.00 265000000.00 4684000000.00 3553000000.00 0.00 0.00 0.00 0.00 1000000.00 280000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 70000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 16000000.00 385000000.00 0.00 -2870000000.00 0.00 -1952000000.00 0.00 0.00 0.00 0.00 0.00 0.00 2000000.00 0.00 0.00 0.00 0.00 220000000.00 991000000.00 148000000.00 0.00 0.00 -1357000000.00 425000000.00 0.00 425000000.00 1892000000.00 2317000000.00